VACCINE MENINGITIS CJ A+C+W135+Y,monod.+dil.0.5ml (Nimenrix)
Valid Article
VACCINE MENINGITIS CONJ. A+C+W135+Y
Menveo® vaccine is the first choice. However, it is not always available at supply centre level. In this case, Menactra® or Nimenrix® (non-standard) vaccines can be an alternative. Contact your section pharmacist for more information.
Therapeutic Action
Meningococcal Group A, C, W-135 and Y inactivated conjugate vaccine
Indications
Active immunisation against meningitis due to Neisseria meningitidis groups A, C, W-135 and Y in infants, children, adolescents and adults at risk of invasive disease (e.g. persons with functional or surgical asplenia)
.
Instructions for use
Must be given as IM injection.
Depending on the vaccine used, vaccination age for infants may vary:
- Menveo®: from 2 months of age
- Menactra®: from 9 months of age
- Nimenrix®: from 6 weeks of age
Depending on the vaccine used, composition and dilution may vary:
- Menveo®: lyophilised active component to be reconstituted with the diliuent before use
- Menactra®: liquid vaccine, ready-to-use
- Nimenrix®: lyophilised active component to be reconstituted with the diluent before use
Precautions for Use
As with all injectable vaccines and/or immunoglobulins, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the product.
Storage
- Keep refrigerated between 2°C and 8°C - Protect from sunlight
- Do not freeze.
- The vaccine vial monitor (VVM) is mandatory on each vaccine in multi-dose presentation.